Table 1.
Haemophilus parasuis strains used in the present study
| Strains | Susceptibility 1 to | lsgB 2 | group1 vtaA 2 | MLST 3 | Serovar | |
|---|---|---|---|---|---|---|
| Serum | Phagocytosis | |||||
| Nasal strains | ||||||
| F9 | S | S | - | - | C | 6 |
| ND14-1 | S | S | - | - | C | 7 |
| SC14-1 | S | S | - | - | C | 15 |
| MU21-2 | S | S | - | - | C | 7 |
| SL3-2 | S | S | - | + | B | 10 |
| Strains from lesions | ||||||
| Nagasaki | R | R | + | + | A | 5 |
| P015/96 | R | R | + | + | A | 5 |
| ER-6P | R | R | + | + | A | 15 |
| 264/99 | R | R | + | + | A | 10 |
| IT29205 | R | R | + | + | A | 4 |
| 2725 | S | R | + | + | A | 10 |
| 373/03A | I | R | - | + | A | 7 |
| PV1-12 | S | R | - | + | B | 15 |
| 9904108 | S | R | - | - | C | 4 |
1(S) sensitive; (I) intermediate; (R) resistant.
2(+) gene present; (−) gene absent.
3Cluster associated with isolates from systemic lesions (A); with nasal isolation (C); or cluster with no statistical association with clinical origin (B) [2].